103 related articles for article (PubMed ID: 29107073)
1. Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma.
Krupar R; Hautmann MG; Pathak RR; Varier I; McLaren C; Gaag D; Hellerbrand C; Evert M; Laban S; Idel C; Sandulache V; Perner S; Bosserhoff AK; Sikora AG
Am J Pathol; 2018 Jan; 188(1):72-83. PubMed ID: 29107073
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
[TBL] [Abstract][Full Text] [Related]
3. The association of (18)F-FDG PET and glucose metabolism biomarkers GLUT1 and HK2 in p16 positive and negative head and neck squamous cell carcinomas.
Baschnagel AM; Wobb JL; Dilworth JT; Williams L; Eskandari M; Wu D; Pruetz BL; Wilson GD
Radiother Oncol; 2015 Oct; 117(1):118-24. PubMed ID: 26328941
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
[TBL] [Abstract][Full Text] [Related]
5. High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma.
Chen YJ; Rau KM; Chien CY; Fang FM; Huang TL; Chiu TJ
Asian Pac J Cancer Prev; 2011; 12(3):649-55. PubMed ID: 21627359
[TBL] [Abstract][Full Text] [Related]
6. Induction of CD44 variant 9-expressing cancer stem cells might attenuate the efficacy of chemoradioselection and Worsens the prognosis of patients with advanced head and neck cancer.
Aso T; Matsuo M; Kiyohara H; Taguchi K; Rikimaru F; Shimokawa M; Segawa Y; Higaki Y; Umeno H; Nakashima T; Masuda M
PLoS One; 2015; 10(3):e0116596. PubMed ID: 25751671
[TBL] [Abstract][Full Text] [Related]
7. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
[TBL] [Abstract][Full Text] [Related]
8. p53 expression in concurrent chemoradiotherapy with docetaxel for head and neck squamous cell carcinoma.
Oridate N; Homma A; Higuchi E; Suzuki F; Hatakeyama H; Mizumachi T; Furusawa J; Taki S; Furuta Y; Fukuda S
Auris Nasus Larynx; 2009 Feb; 36(1):57-63. PubMed ID: 18472237
[TBL] [Abstract][Full Text] [Related]
9. Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different.
Krupar R; Robold K; Gaag D; Spanier G; Kreutz M; Renner K; Hellerbrand C; Hofstaedter F; Bosserhoff AK
Virchows Arch; 2014 Sep; 465(3):299-312. PubMed ID: 25027580
[TBL] [Abstract][Full Text] [Related]
10. Recurrent HNSCC Harbor an Immunosuppressive Tumor Immune Microenvironment Suggesting Successful Tumor Immune Evasion.
Watermann C; Pasternack H; Idel C; Ribbat-Idel J; Brägelmann J; Kuppler P; Offermann A; Jonigk D; Kühnel MP; Schröck A; Dreyer E; Rosero C; Nathansen J; Dubrovska A; Tharun L; Kirfel J; Wollenberg B; Perner S; Krupar R
Clin Cancer Res; 2021 Jan; 27(2):632-644. PubMed ID: 33109740
[TBL] [Abstract][Full Text] [Related]
11. EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity.
Chang JW; Gwak SY; Shim GA; Liu L; Lim YC; Kim JM; Jung MG; Koo BS
Oral Oncol; 2016 Jan; 52():66-74. PubMed ID: 26604082
[TBL] [Abstract][Full Text] [Related]
12. Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients.
Farnebo L; Tiefenböck K; Ansell A; Thunell LK; Garvin S; Roberg K
Int J Cancer; 2013 Oct; 133(8):1994-2003. PubMed ID: 23564498
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of glycolysis markers in head and neck squamous cell carcinoma: a meta-analysis.
Wang Y; Li Y; Jiang L; Ren X; Cheng B; Xia J
Aging (Albany NY); 2021 Feb; 13(5):7284-7299. PubMed ID: 33653965
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy.
Homma A; Furuta Y; Oridate N; Nakano Y; Kohashi G; Yagi K; Nagahashi T; Yagi K; Nagahashi T; Fukuda S; Inoue K; Inuyama Y
Clin Cancer Res; 1999 Apr; 5(4):801-6. PubMed ID: 10213215
[TBL] [Abstract][Full Text] [Related]
15. Prostacyclin-synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy.
Camacho M; Piñeiro Z; Alcolea S; García J; Balart J; Terra X; Avilés-Jurado FX; Soler M; Quer M; León X; Vila L
J Pathol; 2015 Jan; 235(1):125-35. PubMed ID: 25256272
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of cyclin D1 and p16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy.
Higuchi E; Oridate N; Homma A; Suzuki F; Atago Y; Nagahashi T; Furuta Y; Fukuda S
Head Neck; 2007 Oct; 29(10):940-7. PubMed ID: 17563903
[TBL] [Abstract][Full Text] [Related]
19. Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience.
Ock CY; Keam B; Lim Y; Kim TM; Lee SH; Kwon SK; Hah JH; Kwon TK; Kim DW; Wu HG; Sung MW; Heo DS
Head Neck; 2016 Feb; 38(2):277-84. PubMed ID: 26104823
[TBL] [Abstract][Full Text] [Related]
20. Lactate as a predictive marker for tumor recurrence in patients with head and neck squamous cell carcinoma (HNSCC) post radiation: a prospective study over 15 years.
Blatt S; Voelxen N; Sagheb K; Pabst AM; Walenta S; Schroeder T; Mueller-Klieser W; Ziebart T
Clin Oral Investig; 2016 Nov; 20(8):2097-2104. PubMed ID: 26728026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
